As more than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in Vivo Efficacy Studies to offer better predictability and anticipate clinical results.
Syncrosome offer relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds.
We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored in vivo experimental protocols to give you appropriate answers.
13TH ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM
FOR PARTNERING & INVESTMENT
19TH - 20TH FEBRUARY 2020, HILTON ZURICH AIRPORT HOTEL, SWITZERLAND
EXHIBITORS AT THE #Sachs_ELSF FORUM
Sachs Associates Switzerland AG
Sachs Associates Ltd.
T: +44 203 463 4890
© COPYRIGHT 2023. ALL RIGHTS RESERVED.